The immune response in multiple sclerosis
S Rodríguez Murúa, MF Farez… - Annual Review of …, 2022 - annualreviews.org
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and neurodegenerative
disease that affects the central nervous system (CNS). MS is characterized by immune …
disease that affects the central nervous system (CNS). MS is characterized by immune …
From target discovery to clinical drug development with human genetics
The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …
decades were anticipated to result in many innovative therapies. Here we investigate the …
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic
inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic …
inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic …
Treatment of axial spondyloarthritis: an update
Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the
past two decades. With advances in the discernment of immunopathogenesis of this …
past two decades. With advances in the discernment of immunopathogenesis of this …
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
D Baeten, M Østergaard, JCC Wei, J Sieper… - Annals of the …, 2018 - ard.bmj.com
Objectives To evaluate the efficacy and safety of risankizumab, a humanised monoclonal
antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing …
antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing …
Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis
A Deodhar, LS Gensler, J Sieper, M Clark… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …
The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing
Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major
revision of the TH subset paradigm and substantial progress has been made in deciphering …
revision of the TH subset paradigm and substantial progress has been made in deciphering …
Innate and adaptive immunity in inflammatory bowel disease
A Geremia, P Biancheri, P Allan, GR Corazza… - Autoimmunity …, 2014 - Elsevier
Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC).
The exact cause of IBD remains unknown. Available evidence suggests that an abnormal …
The exact cause of IBD remains unknown. Available evidence suggests that an abnormal …
Five years of GWAS discovery
The past five years have seen many scientific and biological discoveries made through the
experimental design of genome-wide association studies (GWASs). These studies were …
experimental design of genome-wide association studies (GWASs). These studies were …
Effector T helper cell subsets in inflammatory bowel diseases
The gastrointestinal tract is a site of high immune challenge, as it must maintain a delicate
balance between tolerating luminal contents and generating an immune response toward …
balance between tolerating luminal contents and generating an immune response toward …